The JI Acurri Cytometers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kinoshita, T.
Right arrow Articles by Nussenzweig, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kinoshita, T.
Right arrow Articles by Nussenzweig, V.

The Journal of Immunology, Vol 138, Issue 9 2994-2998, Copyright © 1987 by American Association of Immunologists

ARTICLES

A high m.w. form of decay-accelerating factor (DAF-2) exhibits size abnormalities in paroxysmal nocturnal hemoglobinuria erythrocytes

T Kinoshita, SI Rosenfeld and V Nussenzweig

Decay-accelerating factor (DAF) is a 70,000 Mr membrane protein that inhibits the amplification of the complement cascade on cell surfaces. Monoclonal antibodies against different epitopes of the 70,000 Mr DAF (DAF-1) recognize a second band at the position of 140,000 Mr on a Western blot of total red cell ghost proteins or partially pure DAF subjected to electrophoresis under denaturing conditions. Like DAF-1, this polypeptide (DAF-2) has the ability to accelerate decay of the C3 convertase, C4b2a, and to reincorporate into red cell membranes. A population of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) lack DAF-1 and also DAF-2. In addition, in some patients' red cells bearing DAF-1 of normal Mr, DAF-2 is 5,000 to 10,000 Mr smaller than normal. The structural basis for these differences in size of DAF and its PNH variants is unknown.


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
M. Krych-Goldberg, R. E. Hauhart, V. B. Subramanian, B. M. Yurcisin II, D. L. Crimmins, D. E. Hourcade, and J. P. Atkinson
Decay Accelerating Activity of Complement Receptor Type 1 (CD35). TWO ACTIVE SITES ARE REQUIRED FOR DISSOCIATING C5 CONVERTASES
J. Biol. Chem., October 29, 1999; 274(44): 31160 - 31168.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1987 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1987 by The American Association of Immunologists, Inc. All rights reserved.